UNSPSC 51144300: Stimulant or anorexiant morpholines

This classification denotes tetrahydro-1,4-oxazines, substances called morpholines, that tend to increase behavioral alertness, agitation, or excitation, or otherwise, appetite depression, thus the term STIMULANT OR ANOREXIANT MORPHOLINES.

UNSPSC 51144300 Stimulant or anorexiant morpholines is a Class code that in recent state and local procurement activity covers naloxone supply, generic pharmaceuticals, and over-the-counter products acquired by health departments, state health agencies, and cooperative purchasing organizations to support community health initiatives and medication access programs. Recent solicitations show state and local governments purchasing naloxone and drug deactivation systems in bulk for public health distribution, generic multi-source pharmaceuticals through cooperative purchasing vehicles that supply participating jurisdictions across multiple states, and information-gathering on direct-to-manufacturer prescription programs to optimize pharmacy benefit management. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other member jurisdictions). The work itself involves product sourcing, compliance with FDA and Drug Supply Chain Security Act requirements, wholesaler coordination, and logistics management.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs before issuing a formal RFP. MMCAP, administered by Minnesota's Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendors to work through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), certify cGMP and DSCSA compliance, maintain $5 million commercial general liability insurance, and pay a 3 percent administrative fee on contract purchases. The MMCAP procurement emphasizes price competitiveness (weighted 75 percent of evaluation) and serves participating state and local facilities across multiple jurisdictions.